Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: Utility of bortezomib therapy in early graft dysfunction

Annals of Pharmacotherapy

Volumn 46, Issue 1, 2012, Pages

  Stuckey, Linda J ^a   Kamoun, Malek ^a,b   Chan, Kevin M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibody mediated rejection; Bortezomib; Lung transplant

Indexed keywords

ANTIBIOTIC AGENT; BASILIXIMAB; BORTEZOMIB; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; ALLOANTIBODY; BORONIC ACID DERIVATIVE; HLA ANTIGEN; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AIRWAY PRESSURE; ANTIGEN SPECIFICITY; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; DONOR SELECTION; DRUG EFFICACY; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LUNG TRANSPLANTATION; NAUSEA; PLASMAPHERESIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RESPIRATORY FAILURE; THROMBOCYTOPENIA; BLOOD; DONOR; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

BORONIC ACIDS; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LUNG TRANSPLANTATION; MIDDLE AGED; PROTEASE INHIBITORS; PYRAZINES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84855694921     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q509     Document Type: Article

References (19)

1. Package insert. Velcade (bortezomib). Cambridge, MA: Millennium Pharmaceuticals, Inc., December 2010.
2. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008;86:1754-61.
3. Appel JZ 3rd, Hartwig MG, Cantu E 3rd, Palmer SM, Reinsmoen NL, Davis RD. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006;81:1049-57.
4. Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009;6:54-65.
5. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004;4:1033-41.
6. Lau CL, Palmer SM, Posther KE, et al. Influence of panel reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000;69:1520-4.
7. Palmer SM, Davis D, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002;74:799-804.
8. Girnita AL, McCurry KR, Iacono AT, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004;23:1135-41.
9. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005;5:131-8.
10. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest 2004;22:304-11.
11. Macaluso J, Killackey M, Paramesh A, et al. Comparative study of bortezomib therapy for antibody-mediated rejection. Presented at: Concurrent Session 60: Therapy of antibody-mediated rejection. American Transplant Congress, Philadelphia, PA, May 3, 2011.
12. Woodle ES, Light J, Franklin C, et al. A multicenter, prospective, collaborative evaluation of proteasome inhibition for the treatment of antibodymediated rejection in solid organ transplantation. Presented at: Concurrent Session 60: Therapy of antibody-mediated rejection. American Transplant Congress, Philadelphia, PA, May 3, 2011.
13. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011;11:1359-67.
14. Appel JZ 3rd, Hartwig MG, Davis RD, Reinsmoen NL. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Human Immunology 2005;66:378-86.
15. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal M. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008;8:2607-17.
16. Schmidt N, Alloway RR, Sadaka B, Wall G, Shields AR, Woodle ES. Intermediate-term global toxicity analysis of proteasome inhibitor-based antihumoral therapy. Presented at: Concurrent Session 75: Antibodies. American Transplant Congress, Philadelphia, PA, May 4, 2011.
17. van Anken E, Romijn EP, Maggioni C, et al. Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity 2003;18:243-53.
18. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009;87:1551-61.
19. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-9.